Anna's Deep Dives

_{Just facts, you think for yourself}

Gene Editing for Drug Development

Gene editing is transforming drug development. CRISPR and other tools enable precise DNA modifications, accelerating drug discovery and identifying disease-causing genes.

In cancer research, gene editing helps scientists find new drug targets. The Open Targets Validation Lab uses CRISPR to study gene functions, expediting drug development for diseases like lung cancer and leukemia.

CRISPR-based therapies are advancing treatments for genetic disorders. In 2023, the UK approved Casgevy, a CRISPR therapy for sickle cell disease and beta thalassemia. In trials, 28 of 29 sickle cell patients had fewer pain crises, while 39 of 42 beta-thalassemia patients no longer needed transfusions.

Artificial intelligence enhances gene editing. Companies like BenevolentAI use AI to identify drug targets, improving clinical trial success rates and reducing research time.

Researchers are mapping genes in 3D to improve drug discovery. Traditional methods miss key genetic interactions. 3D multiomics shortens drug target identification tenfold, making the process more efficient.

Gene editing is also being explored for infectious diseases. Scientists are testing CRISPR-based treatments for HIV, aiming to remove the virus from human DNA. Early trials show promise, but further research is needed.

The gene editing market, valued at $7.39 billion in 2023, is projected to reach $30.78 billion by 2032, driven by demand for treatments for rare diseases and cancer.

Despite its promise, gene editing in drug development faces challenges, including ethical concerns over bioterrorism and unequal access to treatments. Scientists and regulators must collaborate to ensure safety and fairness.

Biomanufacturing: Editing Bacteria to Produce Medicine

Gene editing is revolutionizing biomanufacturing by enabling bacteria to produce medicine, reducing reliance on chemical synthesis. This approach is faster, cheaper, and more sustainable.

CRISPR and base editing allow scientists to reprogram bacterial DNA. Researchers enhance Streptomyces, a bacteria known for producing antibiotics, to increase drug yield. A new base-editing method, eSCBE3-NG-Hypa, has a 97.67% success rate in modifying bacteria for improved efficiency.

Subscribe to Premium to read the rest.